奥氮平与利培酮治疗伴激越症状的精神分裂症或分裂样精神障碍患者的疗效观察

Clinical effects of olanzapine and risperidone in treatment of schizophrenia with agitated symptoms and schizophrenia-like disorders

目的观察奥氮平与利培酮治疗伴激越症状的精神分裂症或分裂样精神障碍临床效果。方法选取伴有激越症状的精神分裂症或分裂样精神障碍患者70例，随机分为研究组与对照组，各35例，研究组采用奥氮平口服，对照组采用利培酮口服。结果2组患者治疗3d．7d、14d后PANSS兴奋因子（PANSS—EC）评分均下降，差异有统计学意义（P〈0．01），2组间差异无统计学意义（P〉0．05）。2组总有效率及不良反应发生率差异无统计学意义（P〉0．05）。结论对伴有激越症状的精神分裂症或者分裂样精神障碍采取奥氮平与利培酮都可以获得明显的疗效，不良反应都相对较少。

Objective To observe the effects of olanzapine and risperidone in treatment of schizophrenia with agitated symptoms and schizophrenia-like disorders. Methods A total of 70 schiz- ophrenia patients with agitated symptoms or schizophrenia-like disorders were randomly divided into study group （ （ n = 35 ） ） and control group （ n = 35 ） , with oral administration of olanzapine and risper- idone respectively. Results The PANSS-EC score at 3, 7 and 14 days after treatment were decreased in both groups （P 〈0.01 ）, but with no significant difference between two groups（P 〉 0.05 ）. there was no significant difference in total effective rate and incidence of adverse reaction between two groups （ （P 〉 0.05 ）. Conclusion Both olanzapine and risperidone show efficacy and safety in treatment of schizophrenia with agitated symptoms and schizophrenia-like disorder.